Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2259]
News [4611]
Articles [190]
Editorials [8]
Conferences [135]
elearning [9]
ESMO 2018: Avelumab plus axitinib significantly improve PFS in untreated renal cell carcinoma
ESMO 2018: Avelumab plus axitinib significantly improve PFS in untreated renal cell carcinoma
ESMO 2018: Local radiotherapy improves survival in metastatic prostate cancer with low disease burden
ESMO 2018: Local radiotherapy improves survival in metastatic prostate cancer with low disease burden
ESMO 2018: Drugs for treating breast cancer in women are effective and well tolerated in men
ESMO 2018: Drugs for treating breast cancer in women are effective and well tolerated in men
ESMO 2018: Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer
ESMO 2018: Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer
ESMO 2018: Erlotinib improves progression-free survival in early mutated non-small cell lung cancer
ESMO 2018: Erlotinib improves progression-free survival in early mutated non-small cell lung cancer
ESMO 2018: Zoledronic acid improves disease-free survival in premenopausal HR early breast cancer
ESMO 2018: Zoledronic acid improves disease-free survival in premenopausal HR early breast cancer
ESMO 2018: Targeting specific genomic mutation in breast cancer improves outcomes, first study shows
ESMO 2018: Targeting specific genomic mutation in breast cancer improves outcomes, first study shows
ESMO 2018: Some patients with metastatic triple negative breast cancer live longer with immunotherapy
ESMO 2018: Some patients with metastatic triple negative breast cancer live longer with immunotherapy
ESMO 2018: New option for women with advanced breast cancer resistant to hormone therapy
ESMO 2018: New option for women with advanced breast cancer resistant to hormone therapy
ESMO 2018: Shorter-course trastuzumab could be an option in HER2 positive early breast cancers
ESMO 2018: Shorter-course trastuzumab could be an option in HER2 positive early breast cancers

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation